Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 5/20 | 0.65 |
| ▸ | RECQL | P46063 | 1/20 | 0.57 |
| ▸ | FAAH | O00519 | 1/20 | 0.57 |
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
| ▸ | OXER1 | Q8TDS5 | 2/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | GLA | P06280 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.40 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13286462 | 0.86 | TSHR (0.62) | TSHRRECQLFAAHMEN1KMT2A | |
| SCHEMBL12346213 | 0.86 | FAAH (0.73) | TSHRRECQLFAAHMEN1KMT2A | |
| SCHEMBL20814153 | 0.83 | GAA (0.61) | TSHRRECQLFAAHKMT2AGAA | |
| SCHEMBL23085256 | 0.83 | RECQL (0.83) | TSHRRECQLMEN1KMT2AGAA | |
| SCHEMBL15399777 | 0.83 | TSHR (0.65) | TSHRRECQLFAAHMEN1KMT2A | |
| SCHEMBL9618659 | 0.81 | FAAH (0.81) | TSHRRECQLFAAHMEN1KMT2A | |
| SCHEMBL28238018 | 0.81 | TSHR (1.00) | TSHRRECQLMEN1KMT2AGAA | |
| SCHEMBL50039 | 0.81 | TSHR (1.00) | TSHRRECQLMEN1KMT2AGAA | |
| SCHEMBL13376978 | 0.80 | RECQL (0.65) | TSHRRECQLFAAHMEN1KMT2A | |
| SCHEMBL13268369 | 0.79 | FAAH (0.86) | TSHRRECQLFAAHMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120108512-A1 | STABLE PHARMACEUTICAL COMPOSITIONS OF PEPTIDE DERIVATIZED USING AN OXIME LINKER | NOVO NORDISK HEALTH CARE AG (CH) | 2012-05-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120108512-A1 | STABLE PHARMACEUTICAL COMPOSITIONS OF PEPTIDE DERIVATIZED USING AN OXIME LINKER | PTMS, NGLY1, IAPP | TSHR 553/4885RECQL 4391/4885FAAH 2400/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.